WO2006005535A1 - Reagents for diagnosis and therapy of latex allergy and method for the preparation of the same - Google Patents
Reagents for diagnosis and therapy of latex allergy and method for the preparation of the same Download PDFInfo
- Publication number
- WO2006005535A1 WO2006005535A1 PCT/EP2005/007405 EP2005007405W WO2006005535A1 WO 2006005535 A1 WO2006005535 A1 WO 2006005535A1 EP 2005007405 W EP2005007405 W EP 2005007405W WO 2006005535 A1 WO2006005535 A1 WO 2006005535A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- latex
- serum
- nal
- exchange chromatography
- anion
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 47
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 19
- 208000007811 Latex Hypersensitivity Diseases 0.000 title claims abstract description 15
- 206010039251 Rubber sensitivity Diseases 0.000 title claims abstract description 15
- 201000005391 latex allergy Diseases 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 238000002560 therapeutic procedure Methods 0.000 title claims abstract description 10
- 238000003745 diagnosis Methods 0.000 title abstract description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 95
- 108090000623 proteins and genes Proteins 0.000 claims description 95
- 229920000126 latex Polymers 0.000 claims description 93
- 239000004816 latex Substances 0.000 claims description 91
- 229920006173 natural rubber latex Polymers 0.000 claims description 52
- 210000002966 serum Anatomy 0.000 claims description 37
- 239000000203 mixture Substances 0.000 claims description 36
- 239000013566 allergen Substances 0.000 claims description 35
- 239000000284 extract Substances 0.000 claims description 29
- 238000001556 precipitation Methods 0.000 claims description 28
- 239000002244 precipitate Substances 0.000 claims description 25
- 238000005571 anion exchange chromatography Methods 0.000 claims description 24
- 239000006228 supernatant Substances 0.000 claims description 22
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 21
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 21
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 20
- 238000005119 centrifugation Methods 0.000 claims description 20
- 239000001166 ammonium sulphate Substances 0.000 claims description 18
- 230000000172 allergic effect Effects 0.000 claims description 14
- 208000010668 atopic eczema Diseases 0.000 claims description 14
- 238000013375 chromatographic separation Methods 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 14
- 244000043261 Hevea brasiliensis Species 0.000 claims description 12
- 239000000872 buffer Substances 0.000 claims description 10
- 238000001514 detection method Methods 0.000 claims description 10
- 238000004255 ion exchange chromatography Methods 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 7
- 101000608757 Homo sapiens Galectin-3 Proteins 0.000 claims description 6
- 238000004587 chromatography analysis Methods 0.000 claims description 5
- 238000000338 in vitro Methods 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 5
- 238000009007 Diagnostic Kit Methods 0.000 claims description 4
- 238000010828 elution Methods 0.000 claims description 4
- 239000011347 resin Substances 0.000 claims description 4
- 229920005989 resin Polymers 0.000 claims description 4
- 102000014914 Carrier Proteins Human genes 0.000 claims description 3
- 108010078791 Carrier Proteins Proteins 0.000 claims description 3
- 239000011324 bead Substances 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 3
- 238000001042 affinity chromatography Methods 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000011521 glass Substances 0.000 claims description 2
- 230000002209 hydrophobic effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000001542 size-exclusion chromatography Methods 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 229940043517 specific immunoglobulins Drugs 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 claims 2
- 238000004458 analytical method Methods 0.000 claims 1
- 206010016946 Food allergy Diseases 0.000 abstract description 3
- 201000005301 fruit allergy Diseases 0.000 abstract description 3
- 229960004784 allergens Drugs 0.000 description 23
- 238000003556 assay Methods 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 206010020751 Hypersensitivity Diseases 0.000 description 11
- 238000010181 skin prick test Methods 0.000 description 11
- 229920001971 elastomer Polymers 0.000 description 10
- 230000007815 allergy Effects 0.000 description 9
- 208000026935 allergic disease Diseases 0.000 description 8
- 230000009257 reactivity Effects 0.000 description 8
- 230000035945 sensitivity Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 206010070834 Sensitisation Diseases 0.000 description 7
- 239000002245 particle Substances 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 3
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229920003211 cis-1,4-polyisoprene Polymers 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000000428 dust Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000005185 salting out Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 230000002009 allergenic effect Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000000703 high-speed centrifugation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229920003052 natural elastomer Polymers 0.000 description 2
- 229920001194 natural rubber Polymers 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 101710151325 B2 protein Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241001203952 Feia Species 0.000 description 1
- 101800002189 Hevein Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 101000952180 Morus alba Mulatexin Proteins 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 1
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229940074608 allergen extract Drugs 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012502 diagnostic product Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- WKMZPSWMEXVKKG-XITFREQTSA-N hevein Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CS)C(=O)NCC(=O)OC(=O)CC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)[C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O)CC1=CNC2=CC=CC=C12 WKMZPSWMEXVKKG-XITFREQTSA-N 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920001195 polyisoprene Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- -1 sterol glycosides Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
Definitions
- the present invention relates to reagents for diagnosis and/or therapy of latex allergy or fruit allergy and to a method for the preparation of the reagents.
- Latex "sensitization” or “sensitivity” is defined as the presence of specific IgE antibodies to latex allergens in an individual's serum.
- Latex "allergy” describes the elicitation of immediate-type allergic symptoms by contact with latex or latex products in a sensitized individual.
- the composition of natural rubber latex is rather complex and it contains a variety of substances like water, rubber (c/s-1 ,4-polyisoprene), proteins, resins, sugars, ash, and sterol glycosides.
- fresh latex is mixed with ammonia to a final concentration of 200 mmol/L to avoid coagulation and then termed ammoniated latex (AL).
- NAL non-ammoniated latex
- the first step in the diagnosis of type I allergy to NRL is to record a comprehensive clinical history of allergic symptoms to NRL.
- necessary confirmatory tests are performed to identify a state of sensitization.
- the most commonly used confirmatory tests are the skin prick test (SPT) and the serum test for latex-specific IgE antibodies. Standardized SPT extracts and well-characterized allergen mixtures for IgE determination are therefore important prerequisites to diagnose a latex allergy.
- NAL was described as the most attractive candidate latex for further development because of its stability and ease of quality control 3 .
- Ebo et al. (J Allergy Clin Immunol. 1997 Nov; 100(5):618-23) carried out a comparative study of IgE antibody detection methods including SPT. They used an NAL extract (Diagnostic Products Corp) that showed a sensitivity of 68% and a specificity of 100%.
- NAL extract Diagnostic Products Corp
- a Finish study the diagnostic performance of a SPT reagent based on latex C-serum of NAL from Stallergenes (Fresnes, France) was examined 4 .
- an additional SPT extract is available from ALK-Abello (H ⁇ rsholm, Denmark), which is based on latex C-serum of NAL available.
- allergists who wish to perform diagnostic skin tests may prepare their own in-house latex extracts from gloves, especially in case in the respective country, e.g. in the USA, there is no standardized latex skin testing reagent licensed by the corresponding drug approval organisation (e.g. FDA).
- radioallergosorbent assay Assay 1
- ELISA enzyme-linked immunosorbent assay
- DPC Microplate Alastat Three in vitro assays (DPC Microplate Alastat, Pharmacia CAP system FEIA, and Hycor HYTECH) were compared for the detection of natural rubber latex- specific IgE antibody 7 .
- the Pharmacia CAP System and DPCs Alastat displayed a diagnostic specificity of 97% and a 76 or 73% diagnostic sensitivity, respectively, when compared with the latex skin test with the Greer experimental latex reagent.
- RAST kit is probably the latex RAST k82 produced by Pharmacia Diagnostics and its enzyme-linked immunosorbant assay (Pharmacia CAP system).
- a further new latex RAST from Pharmacia Diagnostics is based on k82 but spiked with a recombinant Hev b 5 (rHev b 5) molecule.
- RASTs based on recombinant latex allergens are available.
- Recombinant Hev b 1 , 2, 3, 6.01 , 6.02, 8, 9, and 11 are available as fusion proteins with the maltose binding protein (MBP), rHev b 5 without MBP.
- MBP maltose binding protein
- EP 704 457 describes allergenic proteins designated as Hev b IV 1 Hev b Il or Hev b III.
- WO 01/61305 describes latex allergens selected from rubber elongation factor (REF or Hev b 1), rubber particle associated protein (Hev b 3), acidic 16 KD protein (Hev b 5) and hevein (Hev b 6.02).
- Fresh latex contains about 1-2% proteins and can be separated by high speed centrifugation into three main fractions: (i) a white upper layer or rubber particles; (ii) an aqueous layer (C-serum) containing the cytoplasm from the cells of the latex vessels; and (iii) the bottom fraction (B-serum), which consists mainly of the vacuole-like lutoids).
- a technical problem underlying the present invention is to provide improved reagents for diagnosis and therapy of latex and related allergies.
- the present invention provides a method for the production of a composition containing substantially all natural human IgE binding proteins of natural rubber latex (NRL) comprising the step of preparing one or more protein fraction(s) from NRL or one or more exctract(s) thereof by fractionated precipitation and/or chromatographic separation.
- NRL natural rubber latex
- composition generally comprises one or more protein fractions derived from NRL (or any extract or fraction thereof).
- natural rubber latex means all rubber latexes obtainable from any natural source. It has been observed that in raw latex the amount of proteins and their molecular weight distribution vary considerably among different sources of raw material attributed to factors such as the origin, growing and maturation conditions (climate, season, soil) 14 ' 15 . However, in case NRL is collected from a particular clone of the Hevea brasiliensis tree (e.g. Hevea hrasiliensis Rubber Research Institute of Malaysia clone RRIM 600), by means of a standardized preparation procedure, the protein content and specificity are uniform and reproducible 16 . Therefore, it is preferred that the NRL is from H. brasiliensis. Preferably, the NRL is non-ammoniated latex (NAL).
- NAL non-ammoniated latex
- natural human IgE binding proteins of natural rubber latex means all proteins present in NRL that can act as an allergen in humans and thus contribute to latex allergy or at least sensitisation. It is an important aspect of the present invention that the compositions obtainable by the herein described methods comprise all naturally allergens which may be present in natural rubber latex. Therefore the compositions comprise not only single allergens but all allergens occurring in natural latex rubber.
- extract of NRL comprises any fraction or modified solution or suspension or emulsion derived from NRL as long as said extract contains all natural latex allergens according to the above definition.
- NRL extracts of NRL
- NAL is obtained by centrifugation, preferably high speed centrifugation yielding the above-described fractions (i) white creamy layer of rubber particles, (ii) B-serum (bottom) and (Hi) C - serum between (i) and (ii).
- preferred extracts of NAL are the B-serum and the C-serum.
- fractionating different batches of NRL collected by a standardized preparation procedure yields protein extracts of very similar composition.
- the method according to the present invention preferably comprises the steps of (a) preparing one or more protein fraction(s) of NRL or an extract thereof by fractionated precipitation and
- step (b) subjecting the protein fraction(s) obtained in step (a) to chromatographic separation.
- fractionated precipitation means that proteins can be precipitated by causing perturbations in the solvent with respect to pH, ionic strength, and temperature.
- the precipitate is preferably recovered by commonly used centrifugation steps.
- the properties of the solvent can also be modified by addition of high concentrations of certain salts or of miscible organic solvents. Salts in solution at low ionic strength relative to that of isotonic saline may represent a perturbation that can cause certain proteins to precipitate from solution. On the other hand, salts present in very high concentrations with ionic strength much greater than that of tissue media will cause the precipitation of many proteins. Precipitation occurs by neutralization of surface charges by the salt, by reducing the chemical activity of the protein, and by diminishing the effective concentration of the water.
- salting out This is called “salting out” of proteins.
- concentration of any salt necessary to cause precipitation of a particular protein is related to the number and distribution of charges and of nonionic polar groups on the surface of the protein, and to the number and distribution of hydrophobic residues exposed and rendered dominant as the charges are neutralized.
- the size and shape of the protein also contribute to the relative ease of precipitability.
- Ammonium sulfate is the precipitant used most frequently in the salting out of proteins.
- proteins of latex C- or B-serum are fractionated by different concentrations of ammonium sulfate.
- proteins of the fractions are further separated by ion exchange chromatography as a second step.
- the method of the present invention preferably comprises the steps of: (i) preparing one or more protein fraction(s) of NAL C-serum by fractionated precipitation, (ii) subjecting one or more of the protein fraction(s) obtained in step (a) to chromatographic separation, and (iii) subjecting NAL B-serum to chromatographic separation.
- the chromatographic separation may include ion-exchange chromatography, size exclusion chromatography, hydrophobic chromatography and/or by affinity chromatography, preferable using latex allergen-specific immunoglobulins.
- IEC Ion-exchange chromatography
- IEC is the preferred chromatographic technique of the present invention.
- IEC is designed specifically for the separation of ionic or ionisable compounds.
- IEC differs from other types of liquid chromatography in that the stationary phase carries ionisable functional groups, fixed by chemical bonding to the stationary phase. To satisfy requirements for electrical neutrality, these fixed charges will carry a counterion of opposite sign. This counterion is not fixed and can be displaced.
- Two separate events are involved in IEC. First the binding of the protein to the fixed charges and second the elution or displacement of the protein from the fixed charges by a new counterion with a greater affinity for the fixed charges than the protein.
- anion-exchange chromatography is used for the chromatographic separation of NRL exctracts or protein fractions thereof, e.g. NAL, NAL C- or B-serum or precipitates obtained by fractionated precipitation, preferably salting out using ammonium sulphate, of NRL (e.g. NAL), NAL B- or C- serum.
- MonoBeads (Pharmacia, Uppsala, Sweden) are used as ion media, which are based on 10 ⁇ m beaded hydrophilic polystyrene/divinyl benzene resin.
- the Beads are substituted with quaternary amine groups to yield the strong anion exchanger, MonoQ.
- the stability of the MonoBeads matrix together with controlled synthesis and column packing procedures ensure very reproducible separations both overtime and from column to column.
- chromatographic resins in particular ion-exchange resins, are suitable as well.
- examples include Agarose, Sepharose, Sephadex, Sephacryl, Sephacel.
- a preferred embodiment of the anion-exchange chromatography is carried out in a buffer of 10 to 50 mM, preferably 15 to 30 mM, in particular 20 mM Tris-HCI, pH 7 to 7.8, preferably 7.3 to 7.6, in particular 7.5 with a linear elution gradient of 0 to 1 M NaCI.
- a buffer of 10 to 50 mM preferably 15 to 30 mM, in particular 20 mM Tris-HCI, pH 7 to 7.8, preferably 7.3 to 7.6, in particular 7.5 with a linear elution gradient of 0 to 1 M NaCI.
- other forms of gradients e.g. step gradients
- other buffers e.g. phosphate buffers
- elution salts e.g. KCI
- the fractionated precipitation is carried out by changing the pH and/or ionic strength of the NRL or the extract(s) thereof and/or by introducing a denaturing agent and/or salt thereinto.
- the addition of salts for fractionated precipitation is most preferred. Suitable salts include ammonium sulphate, NaCI and/or Na 2 SO 4 . Alternatively, organic solvents such as ethanol or acetone may be used (instead of salts).
- organic solvents such as ethanol or acetone may be used (instead of salts).
- the fractionated precipitation is carried out by
- NRL NAL C-serum
- the above fractionated precipitation can be applied to any NRL (e.g. NAL) or any other extract derived from NRL.
- composition containing substantially all natural human IgE binding proteins of natural rubber latex comprises all relevant allergens. Therefore the different fractions obtained by the purification methods are preferably tested for the presence of allergens with sera obtained from patients showing allergic reactions against latex.
- the single fractions obtained by fractionated precipitation and/or chromatographic separation are reacted with sera from latex allergic subjects.
- the single fractions may be separated for example by an SDS-PAGE and the Nitrocellulose - blotted fractions may be incubated with either a serum pool obtained from latex allergic subjects or with individual sera of latex allergic subjects.
- the IgE antibodies are identified with anti-lgE-antibodies (preferably obtained from an animal) labelled with either a radioactive component or an enzyme or a dye well known to the person skilled in the art. Furthermore control lanes are provided on the separation gels. By this methods all those fractions can be identified which comprise the naturally occurring proteins of natural rubber latex to which human IgE antibodies may bind.
- the IgE antibodies containing sera are obtained from patients which are allergic against latex or from laboratory animals.
- compositions which comprise all proteins of natural rubber latex to which human IgE antibodies bind.
- the advantage of such composition is that all possible allergens are contained therein.
- the different protein fractions obtained by fractionated precipitation and/or chromatography may be combined, in order to yield a single composition containing all latex allergens at concentrations sufficient to detect allergen specific IgE antibodies.
- composition(s) obtained by the method defined above contain(s) the allergenic protein of NRL at a higher concentration as the source material (NRL itself or the exctract(s) thereof such as NAL B- or C-serum). Whereas the connection of such components to IgE antibodies do not bind is substantially included.
- the method of the present invention provides protein compositions which can successfully be used in in vitro diagnosis and/or therapy (or for the preparation of a diagnostic and/or pharmaceutical composition (medicament), preferably of latex sensitisation or allergy.
- a further embodiment of the present invention relates to a composition containing substantially all natural human IgE binding proteins of natural rubber latex (NRL) obtainable by the method defined above.
- composition preferably contains protein fractions prepared by
- step (B) subjecting the protein fractions obtained in step (A) to anion-exchange chromatography, and (C) subjecting NAL B-serum to anion-exchange chromatography.
- fractionated precipitation comprises the steps of
- NAL C-serum ammonium sulphate to a concentration of 15 to 35 %, preferably 20 to 30 %, more preferably 22 to 28 %, in particular 25 % saturation,
- the composition contains the following protein fractions (or the composition(s) is/are represented by the following protein fractions): the protein fraction obtained by anion-exchange chromatography of the second precipitate in 10 to 50 mM, preferably 15 to 30 mM, in particular 20 mM Tris-HCI, pH 7 to 7.8, preferably 7.3 to 7.6, in particular 7.5, eluting with 120 to 230 mM, preferably 140 to 210 mM, in particular 150 to 200 mM NaCI; the protein fraction obtained by anion-exchange chromatography of the second precipitate in 10 to 50 mM, preferably 15 to 30 mM, in particular 20 mM Tris-HCI, pH 7 to 7.8, preferably 7.3 to 7.6, in particular 7.5, eluting with 270 to 530 mM, preferably 290 to 510 mM, in particular 300 to 500 mM NaCI; the protein fraction obtained by anion-exchange chromatography of the third precipitate in 10 to 50 mM, preferably 15
- composition(s) or protein fraction(s) is/are immobilised on a solid carrier to yield a corresponding carrier-protein conjugate.
- composition is coated onto or coupled to the carrier in the carrier-protein conjugate of the present invention.
- the carrier may be selected from the group consisting of beads, membranes, dipsticks and glass chips.
- the conjugate of the present invention are especially useful in diagnostic applications such as the detection of latex allergy or sensitisation in humans.
- the present invention also relates to a diagnostic kit comprising the composition and/or the conjugate as defined above in combination with commonly used reagents or means for the detection human IgE antibodies.
- the diagnostic kit of the present invention may be present in all commonly known forms for the detection of human IgE antibodies. Examples include but are not limited to in vivo tests such as Skin Prick Test that measures an allergic reaction to proteins present in the fractions in the patients' skin, or in vitro tests such as ImmunoCAP assays, RAST assays, ELISA, dipstick, histamine release, etc. that measure the presence of anti latex protein IgE antibodies in the sera of patients tested.
- in vivo tests such as Skin Prick Test that measures an allergic reaction to proteins present in the fractions in the patients' skin
- in vitro tests such as ImmunoCAP assays, RAST assays, ELISA, dipstick, histamine release, etc. that measure the presence of anti latex protein IgE antibodies in the sera of patients tested.
- the diagnostic kit is especially useful for the detection of (latex) allergen-specific IgE (in particular in humans).
- the present invention further provides a diagnostic method for the detection of (latex) allergen-specific IgE (e.g. in humans) comprising the step of contacting the composition and/or the conjugate of the present invention with a body fluid (e.g. blood or fractions thereof such as blood serum).
- a body fluid e.g. blood or fractions thereof such as blood serum.
- the contacting with a body fluid also comprises the injection of the composition of the present invention under or into the skin, e.g. by a skin prick text (SPT).
- SPT skin prick text
- the diagnostic method according to the present invention can also be performed as an ImmunoCAP assay, RAST assay, ELISA etc.
- the reagents provided by the method of the invention are also useful as medicaments (or useful for the preparation thereof).
- the inventive composition may be used for the prevention or therapy of latex allergy or latex-fruit syndrome (or for the preparation of a medicament for the mentioned indications).
- the medicament or pharmaceutical composition can contain commonly used pharmaceutically acceptable one or more carriers, vehicles and/or diluents.
- the present invention also relates to a method for the prevention or therapy of the above indications comprising the step of administering the composition or medicament of the present invention to a human patient, particularly suffering from latex allergy or sensitisation and/or fruit allergy.
- Preferred administration methods include the injection via the intramuscular route or the mucosal application such as via the sublingual route.
- the preventive/therapeutic method of the present invention is preferably carried out in the form of a hyposensitisation protocol.
- the protocol may include administration of increasing concentrations of allergen extract over a period of time.
- Figure 1 shows an SDS-PAGE of the four fractions obtained from latex C-serum. Two different batches of latex C-serum were used and protein content compared.
- Figure 2 shows IgE reactivity of 5 serum pools consisting each of 5 sera of latex allergic subjects to a) latex C-serum and the four latex C fractions and b) to latex C-serum and the two latex B fractions. Nitrocellulose-blotted fractions were incubated with the serum pools and bound IgE detected with an 125 l-labeled anti-human IgE antibody (lanes 1-5). Lanes P and N show the buffer control and the control serum pool. Molecular weight markers as indicated.
- Figure 3 demonstrates the existence of Hev b 5, Hev b 6, and Hev b 8 in the latex extracts.
- Nitrocellulose-blotted rHev b 5, rHev b 6, and rHev b 8 were incubated with serum-pools each consisting of three sera of subjects allergic to the respective allergen.
- the serum pool for Hev b 5 was preincubated with fraction C3, the Hev b 6 serum pool with fraction B2 and the Hev b 8 serum pool with C1.
- Bound IgE was detected with an 125 l-labeled anti-human IgE antibody (lanes 1-5).
- Lanes P and N show the buffer control and the control serum pool. Molecular weight markers as indicated.
- Fresh Hevea latex was collected in chilled containers from rubber trees (H. brasiliensis, clone RRIM 600). The latex was centrifuged at 44,00Og at 4 0 C for 1 hour to separate it into three main fractions: a top fraction containing the rubber particles, an aqueous phase, the C-serum, and a "heavy" bottom fraction containing lutoids. The aqueous phase was collected and centrifugation was repeated. The clear aqueous C-serum was freeze dried and stored at - 20°C.
- the bottom fraction containing the lutoids was resuspended in 0.4 mol/L mannitol, resedimented and subjected to repeated alternate freezing and thawing to rupture the lutoids.
- the fluid of the lutoids, the B-serum, was then recovered by centrifugation 17 .
- Precipitates from the ammonium sulphate fractionation were dissolved in 20 mM Tris/HCI, pH 7.5 and desalted by passing through a PD-10 column (Pharmacia, Uppsala, Sweden). Each fraction was applied to a MonoQ HR5/5 column (Pharmacia). In the same way one hundred milligrams lyophilized latex B-serum were dissolved in 20 mM Tris/HCI, pH 7.5 and applied to a a MonoQ HR5/5 column. The unadsorbed proteins were eluted from the column with the same buffer and adsorbed proteins were eluted using a linear gradient of 0-1 M NaCI in 20 mM Tris/HCI, pH 7.5.
- Fraction C1 contained proteins eluted with 150-200 mM NaCI
- fraction C2 proteins eluted with 300-500 mM NaCI, both derived from the 50% (NhU) 2 SO 4 precipitate
- Fraction C3 contained proteins eluted with 300-450 mM NaCI
- C4 with 450-550 mM NaCI both derived from the 75% (NhU) 2 SO 4 precipitate.
- the whole procedure was performed with two different batches of latex C-serum. Five ⁇ g of each fraction was separated by 12 % PAGE and stained with Coomassie brilliant blue (Figure 1). Protein patterns appeared very similar with small differences in the concentration of certain proteins ( Figure 1 , lanes 1 and 2).
- Latex B-serum was directly applied to anion exchange chromatography yielding two fractions. Fraction B1 contained unadsorbed proteins and fraction B2 proteins eluted with 150-250 mM NaCI.
- Example 2 IgE reactivity to latex C- and B-serum
- IgE reactivity to proteins in latex C-serum was observed for pool 1 , 2, and 4 ( Figure 2a, blot C-serum). IgE reactions of these serum pools increased in the latex C- serum fractions especially to proteins in the 40 - 80 kDa range ( Figure 2a, blots C1- C4, lanes 1 , 2, and 4). Serum pool 3 showed weak IgE reactivity to only one protein in latex C-serum ( Figure 2a, blot C-serum, lanes 3) and IgE reactions to at least 6 different proteins were measurable in the latex C-serum fractions.
- the serum pool of 7 house dust mite allergic subjects and the buffer control showed no IgE reactivity in latex B-serum and any of the fractions (Figure 2b, blots B-serum, B1 , and B2, lanes N and P).
- the latex fractions of the present invention contain the important latex allergens Hev b 5, Hev b 6, and Hev b 8.
- Recombinant Hev b 5, rHev b 6, and rHev b 8 were separated by 12% PAGE and blotted onto nitrocellulose.
- Membrane strips were incubated with serum pools each consisting of three sera tested to display IgE to the respective allergens.
- sera were preincubated with 50 ⁇ g protein extract.
- the Hev b 5 serum pool was preincubated with fraction C3, the Hev b 6 serum pool with fraction B2 and the Hev b 8 serum pool with C1.
- Preincubation of the serum pools with the fractions resulted in diminishment or complete abolishment of IgE binding to the recombinant allergens (Figure 3).
- Latex B-B-serum-1 ,3-glucanase (Hev b 2) and a component of the microhelix (Hev b 4) are major latex allergens. J. Nat. Rubber Res. 1996; 10:82-99.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Botany (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002573377A CA2573377A1 (en) | 2004-07-15 | 2005-07-08 | Reagents for diagnosis and therapy of latex allergy and method for the preparation of the same |
US11/632,500 US20070253965A1 (en) | 2004-07-15 | 2005-07-08 | Reagents for Diagnosis and Therapy of Latex Allergy and Method for the Preparation of the Same |
JP2007520724A JP2008505954A (en) | 2004-07-15 | 2005-07-08 | Reagent for diagnosis and treatment of latex allergy, and preparation method thereof |
AU2005261886A AU2005261886A1 (en) | 2004-07-15 | 2005-07-08 | Reagents for diagnosis and therapy of latex allergy and method for the preparation of the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04016656.3 | 2004-07-15 | ||
EP04016656A EP1616877B1 (en) | 2004-07-15 | 2004-07-15 | Reagents for diagnosis and therapy of latex allergy and method for the preparation of the same |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006005535A1 true WO2006005535A1 (en) | 2006-01-19 |
Family
ID=34925768
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2005/007405 WO2006005535A1 (en) | 2004-07-15 | 2005-07-08 | Reagents for diagnosis and therapy of latex allergy and method for the preparation of the same |
Country Status (11)
Country | Link |
---|---|
US (1) | US20070253965A1 (en) |
EP (1) | EP1616877B1 (en) |
JP (1) | JP2008505954A (en) |
CN (1) | CN101018805A (en) |
AT (1) | ATE396200T1 (en) |
AU (1) | AU2005261886A1 (en) |
CA (1) | CA2573377A1 (en) |
DE (1) | DE602004013957D1 (en) |
DK (1) | DK1616877T3 (en) |
ES (1) | ES2303616T3 (en) |
WO (1) | WO2006005535A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105854012A (en) * | 2006-06-29 | 2016-08-17 | 生物技术工具公司 | A method for the production of hydrolyzed allergen |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112146955A (en) * | 2020-09-23 | 2020-12-29 | 深圳市亚辉龙生物科技股份有限公司 | Method for preparing serum |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0704457A1 (en) * | 1994-09-16 | 1996-04-03 | The Board Of The Rubber Research Institute Of Malaysia | Allergenic proteins of natural rubber latex, their production and use in assays |
WO2001061305A2 (en) * | 2000-02-15 | 2001-08-23 | Fit Biotech Oyj Plc | Immunoassays detecting or making use of at least two rubber latexallergens |
-
2004
- 2004-07-15 DK DK04016656T patent/DK1616877T3/en active
- 2004-07-15 EP EP04016656A patent/EP1616877B1/en not_active Not-in-force
- 2004-07-15 ES ES04016656T patent/ES2303616T3/en active Active
- 2004-07-15 AT AT04016656T patent/ATE396200T1/en not_active IP Right Cessation
- 2004-07-15 DE DE602004013957T patent/DE602004013957D1/en active Active
-
2005
- 2005-07-08 WO PCT/EP2005/007405 patent/WO2006005535A1/en active Application Filing
- 2005-07-08 CN CNA200580030971XA patent/CN101018805A/en active Pending
- 2005-07-08 CA CA002573377A patent/CA2573377A1/en not_active Abandoned
- 2005-07-08 JP JP2007520724A patent/JP2008505954A/en active Pending
- 2005-07-08 US US11/632,500 patent/US20070253965A1/en not_active Abandoned
- 2005-07-08 AU AU2005261886A patent/AU2005261886A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0704457A1 (en) * | 1994-09-16 | 1996-04-03 | The Board Of The Rubber Research Institute Of Malaysia | Allergenic proteins of natural rubber latex, their production and use in assays |
WO2001061305A2 (en) * | 2000-02-15 | 2001-08-23 | Fit Biotech Oyj Plc | Immunoassays detecting or making use of at least two rubber latexallergens |
Non-Patent Citations (8)
Title |
---|
ALENIUS H ET AL: "LATEX ALLERGY: FREQUENT OCCURRENCE OF IGE ANTIBODIES TO A CLUSTER OF 11 LATEX PROTEINS IN PATIENTS WITH SPINA BIFIDA AND HISTORIES OF ANAPHYLAXIS", JOURNAL OF LABORATORY AND CLINICAL MEDICINE, ST. LOUIS, MO, US, vol. 123, no. 5, 1994, pages 712 - 720, XP008048269, ISSN: 0022-2143 * |
ALENIUS H ET AL: "THE MAIN IGE-BINDING EPITOPE OF A MAJOR LATEX ALLERGEN, PROHEVEIN, IS PRESENT IN ITS N-TERMINAL 43-AMINO ACID FRAGMENT, HEVEIN", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 156, no. 4, 1996, pages 1618 - 1625, XP001152539, ISSN: 0022-1767 * |
HUFNAGL K ET AL: "Induction of mucosal tolerance with recombinant Hev b 1 and recombinant Hev b 3 for prevention of latex allergy in BALB/c mice", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, OXFORD, GB, vol. 133, 2003, pages 170 - 176, XP002330931, ISSN: 0009-9104 * |
NIETO A ET AL: "Assessment of profilin as an allergen for latex-sensitized patients", ALLERGY, MUNSKGAARD, COPENHAGEN, DK, vol. 57, 2002, pages 776 - 784, XP002330930, ISSN: 0105-4538 * |
SANCHEZ-MONGE R ET AL.: "Isolation and characterization of major banana allergens: identification as fruit class I chitinases", CLINICAL AND EXPERIMENTAL ALLERGY, vol. 29, 1999, pages 673 - 680, XP002330932 * |
WAGNER S ET AL.: "Characterization of cross-reactive bell pepper allergens involved in the latex-fruit syndrome", CLINICAL AND EXPERIMENTAL ALLERGY, vol. 34, no. 11, November 2004 (2004-11-01), pages 1739 - 1746, XP002356494 * |
WAGNER S ET AL.: "Hev b 9, an enolase and a new cross-reactive allergen from Hevea latex and molds", EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 267, 2000, pages 7006 - 7014, XP002330929 * |
ZHIPING CHEN ET AL: "Isolation and identification of hevein as a major IgE-binding polypeptide in Hevea latex", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, MOSBY - YEARLY BOOK, INC, US, vol. 99, no. 3, 1997, pages 402 - 409, XP002957470, ISSN: 0091-6749 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105854012A (en) * | 2006-06-29 | 2016-08-17 | 生物技术工具公司 | A method for the production of hydrolyzed allergen |
Also Published As
Publication number | Publication date |
---|---|
JP2008505954A (en) | 2008-02-28 |
DE602004013957D1 (en) | 2008-07-03 |
US20070253965A1 (en) | 2007-11-01 |
CN101018805A (en) | 2007-08-15 |
EP1616877A1 (en) | 2006-01-18 |
DK1616877T3 (en) | 2008-09-22 |
EP1616877B1 (en) | 2008-05-21 |
ATE396200T1 (en) | 2008-06-15 |
ES2303616T3 (en) | 2008-08-16 |
CA2573377A1 (en) | 2006-01-19 |
AU2005261886A1 (en) | 2006-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Czuppon et al. | The rubber elongation factor of rubber trees (Hevea brasiliensis) is the major allergen in latex | |
Ogawa et al. | α-Subunit of β-conglycinin, an allergenic protein recognized by IgE antibodies of soybean-sensitive patients with atopic dermatitis | |
Tinghino et al. | Molecular, structural, and immunologic relationships between different families of recombinant calcium-binding pollen allergens | |
Heiss et al. | Identification of a 60 kd cross-reactive allergen in pollen and plant-derived food | |
Stauber et al. | The γ‐aminobutyric‐acid/benzodiazepine‐receptor protein from rat brain: Large‐scale purification and preparation of antibodies | |
CN101215323A (en) | Human AD7C-NTP antigen determinant polypeptide, antibody and application thereof in diagnosis kit | |
US9274114B2 (en) | Prostate kallikrein allergen | |
Alenius et al. | Purification and partial amino acid sequencing of a 27-kD natural rubber allergen recognized by latex-allergic children with spina bifida | |
Waseem et al. | Erythrocyte adducin: Comparison of the α‐and β‐subunits and multiple‐site phosphorylation by protein kinase C and cAMP‐dependent protein kinase | |
JP3747200B2 (en) | Allergenic protein of natural rubber latex, its production and use in analysis | |
Husebekk et al. | Characterization of bovine amyloid proteins SAA and AA | |
Rihs et al. | Recombinant Hev b 1: large‐scale production and immunological characterization | |
Maruyama et al. | Purification and characterization of neutral and acid sphingomyelinases from rat brain | |
US20070253965A1 (en) | Reagents for Diagnosis and Therapy of Latex Allergy and Method for the Preparation of the Same | |
Hussain et al. | Rapidly released allergens from short ragweed pollen: II. Identification and partial purification | |
Nieto et al. | Assessment of profilin as an allergen for latex‐sensitized patients | |
NZ222942A (en) | Mitochondrial autoantigen of primary biliary cirrhosis and fragments, production by genetic engineering methods, diagnostic test and pharmaceutical use | |
AU2002242273C1 (en) | Compositions of multimeric profilin for diagnosis and treatment of allergies | |
Gruber et al. | Development of an epitope‐specific analytical tool for the major peanut allergen Ara h 2 using a high‐density multiple‐antigenic peptide strategy | |
US9724407B2 (en) | Horse allergen and methods | |
Glenner et al. | The immunoglobulin origin of amyloid fibril proteins | |
Brodard | Lol p XI, a new major grass pollen allergen, is a member of a family of soybean trypsin inhibitor-related proteins | |
WO2016013971A1 (en) | Novel allergen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2573377 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007520724 Country of ref document: JP Ref document number: 299/DELNP/2007 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005261886 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11632500 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
ENP | Entry into the national phase |
Ref document number: 2005261886 Country of ref document: AU Date of ref document: 20050708 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005261886 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580030971.X Country of ref document: CN |
|
122 | Ep: pct application non-entry in european phase | ||
WWP | Wipo information: published in national office |
Ref document number: 11632500 Country of ref document: US |